Overview

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

Status:
Not yet recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno PF® Plus Gaap Ofteno PF®, both applied every 12 hours, in patients with open angle glaucoma or ocular hypertension during 90 days

Phase:

Phase 4

Details

Lead Sponsor:

Laboratorios Sophia S.A de C.V.

Treatments:

Brimonidine Tartrate
Dorzolamide
Latanoprost
Timolol